Boswellia is the gum resin of Boswellia serrata, a tree native to Northern Africa, India and the Middle East. It is also called Indian frankincense. Supplements contain extracts of the resin, some standardized to boswellic acids, its triterpene acids. Some extracts also keep the resin's volatile compounds.
Terms and sources
- native to Northern Africa, India and the Middle East
- NCCIH, Boswellia: Usefulness and Safety.
- Indian frankincense
- Riva et al., Phytomedicine, 2016, a trial report below.
- boswellic acids
- Hammer et al. name AKBA, KBBA, β-boswellic acid and 3-acetyl-β-boswellic acid as the main ones. Hammer et al., Nutrients, 2026, a trial report below.
- volatile compounds
- Such as α-thujene. Joseph et al., Biological and Pharmaceutical Bulletin, 2024, a trial report below.
Boswellia in the body
Boswellia is not a nutrient, and the body has no daily requirement for it. Trials in adults without a diagnosis measure pain tests and boswellic acids in blood.
In one trial, blood boswellic acids were higher when an extract was taken with a high-fat meal than fasting. Two α-boswellic acids were detectable only with the meal. Hammer et al. write that blood AKBA after oral intake stays far below the level that blocks 5-lipoxygenase in lab tests.
Terms and sources
- In one trial
- Sterk et al., Planta Medica, 2004, below.
- 5-lipoxygenase
- An enzyme of inflammation signaling that AKBA blocks in lab tests. Hammer et al., Nutrients, 2026, a trial report below.
Safety: what NCCIH says
NCCIH, on safety: "Boswellia is likely to be safe when taken orally." NCCIH adds: "Boswellia serrata extract in doses up to 1,000 mg daily has been safely used in several clinical trials lasting up to 6 months." NCCIH adds: "It has also been used with apparent safety at a dose of 2,400 mg for up to 1 month." NCCIH adds: "Boswellia (frankincense) may be safe to use topically or for aromatherapy."
Terms and sources
- on safety
- Quoted in full from the NCCIH page's safety section; the last sentence is from its Keep in Mind section. NCCIH, Boswellia: Usefulness and Safety.
NCCIH adds: "If you have asthma, follow your health care provider’s recommendations on how to manage your condition. For your safety:" NCCIH adds: "Do not substitute other approaches for treatments recommended or prescribed by your health care provider." NCCIH adds: "Consult your health care provider about adding any complementary health products or practices to your asthma management program. If you take medicine for asthma, talk with your provider before starting to take a dietary supplement. Some dietary supplements and medicines can interact in harmful ways."
NCCIH adds: "No complementary approach has been shown to cure cancer or cause it to go into remission. Some products or practices that have been advocated for cancer treatment may interfere with conventional cancer treatments or have other risks. If you’ve been diagnosed with cancer, you should consult your health care providers before using any complementary health approach."
NCCIH adds: "It is likely safe to use boswellia in amounts commonly found in foods during pregnancy or while breastfeeding. Little is known about whether it’s safe to use boswellia orally in medicinal amounts or to use frankincense during pregnancy or while breastfeeding."
NCCIH, in Keep in Mind: "If you take any type of medicine, talk with your health care provider before using any herbal product; some herbs and medicines interact in harmful ways."
Where boswellia comes from
Boswellia serrata is a tree of the Burseraceae family. Its dried resin has been used in Ayurvedic medicine for centuries. The resin holds volatile compounds, such as terpenes, and non-volatile boswellic acids. Hammer et al. write that four main boswellic acids make up about 14% of the fat-soluble extract fraction.
Terms and sources
- Burseraceae
- Italian Ministry of Health, list of plants for food supplements, 2018.
- for centuries
- Hammer et al., Nutrients, 2026, a trial report below.
- volatile compounds
- Joseph et al., Biological and Pharmaceutical Bulletin, 2024.
- about 14%
- Hammer et al., Nutrients, 2026, a trial report below.
Published studies of boswellia
Most boswellia trials studied people with a diagnosis, often of the joints. Those trials are not listed here, nor are studies of boswellia mixed with other ingredients. Studies of boswellia on the skin, in the mouth or inhaled are not listed either.
We list trials with up to 1,000 mg of Boswellia serrata extract a day.
Terms and sources
- up to 1,000 mg
- NCCIH: "Boswellia serrata extract in doses up to 1,000 mg daily has been safely used in several clinical trials lasting up to 6 months. It has also been used with apparent safety at a dose of 2,400 mg for up to 1 month." NCCIH, Boswellia: Usefulness and Safety.
5 studies in adults without a diagnosis. Against a dummy product, 1 found no difference and 1 had mixed results. 2 compared forms, and 1 compared taking an extract with and without a meal.
12 to 16 people each, where given; one abstract gives no number. Not listed: studies in people with a diagnosis, after surgery or taking medicines. Nor are studies that chose people by a memory or knee pain score. Also not listed: boswellia mixed with other ingredients, or used on the skin, in the mouth or inhaled. Nor are studies that included or may have included people under 18. Also not listed: reviews that include such studies, and studies without an abstract. Nor are trials without a stated random order or comparison group. All 5 trials that qualify are listed.
Our one-line summary comes first. The original is on PubMed.
Show the 5 studies
16 healthy volunteers took single 400 mg doses of two boswellia extracts; blood boswellic acids were higher with one.
Trial · 16 people · Single doses · industry author
Joseph et al., Biological and Pharmaceutical Bulletin, 2024
Terms and sources
- two boswellia extracts
- BFQ-20, a full-spectrum Boswellia serrata extract in a hydrogel made with fenugreek mucilage, and an unformulated boswellia extract. The abstract also names a placebo without saying how it was used.
- higher with one
- Boswellic acids, area under the blood curve: 9,484 with BFQ-20 and 2,366 ng·h/mL unformulated (p < 0.001). α-Thujene, a volatile compound, was not detectable after the unformulated extract.
- industry author
- All four authors work at the research center of Akay Natural Ingredients. We read only the abstract, so we could not check who paid.
Study · Free full text · about 2 min to read
Free full text on J-STAGE under a CC BY-NC license. We could not read the full text. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
16 healthy volunteers took single 400 mg doses of two forms of a Boswellia serrata extract, in turn. One was BFQ-20, held in a hydrogel made with fenugreek mucilage. The other was an unformulated extract. Boswellic acids in blood, as area under the curve, were 9,484 with BFQ-20 and 2,366 ng·h/mL unformulated. α-Thujene, a volatile compound, was detectable only after BFQ-20. Funding: all authors work at Akay Natural Ingredients. We read only the abstract.
12 healthy adults took a boswellia extract and dummy capsules for 28 days each; pain tests did not differ.
Trial · 12 people · 28 days each
Hammer et al., Nutrients, 2026
Terms and sources
- 12 healthy adults
- Aged 18 or older, without chronic pain, regular painkillers or interacting medicines. Each took both products in random order, with 4 weeks between.
- a boswellia extract
- BoswellinSuper, 300 mg twice a day (600 mg a day), from Sabinsa Europe GmbH. By the maker's specification: 75% total boswellic acids, at least 50% β-boswellic acid and 30% AKBA.
- dummy capsules
- Capsules of maltodextrin, identical in look.
- pain tests did not differ
- Pain after a capsaicin patch on the forearm: 43 with boswellia and 47 with dummy capsules, of 100 (p = 0.539). Heat, pinprick, touch and cold tests and mood, sleep and well-being questionnaires did not differ either.
- 28 days each
- No unwanted events were reported with either product. The Results text gives the heat pain threshold with boswellia as 34.77 °C; the table gives 36.84 °C.
Study · Free full text · about 21 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
A pilot trial in Graz gave 12 healthy adults BoswellinSuper, 300 mg twice a day, for 28 days. Each also took dummy capsules for 28 days, in random order. After each period, a capsaicin patch caused pain on the forearm. Pain was 43 with boswellia and 47 with dummy capsules on a 0–100 scale. Heat, pinprick, touch and cold tests and mood, sleep and well-being questionnaires did not differ. No unwanted events were reported. Funding: the City of Graz cultural office paid; the authors declare no conflicts.
12 healthy volunteers took lecithin-formulated and plain boswellia extracts; five of six boswellic acids in blood were higher with lecithin.
Trial · 12 people · Single doses · industry author
Riva et al., Phytomedicine, 2016
Terms and sources
- lecithin-formulated and plain boswellia extracts
- A standardized Boswellia serrata extract and its lecithin formulation, called CSP in the report. Two 250 mg capsules of each, as single doses in random order, open label.
- five of six boswellic acids
- KBA did not differ. The other five were higher and were absorbed faster with the lecithin form, both by weight and by molar amount.
- industry author
- Four of nine authors work at Indena S.p.A. We could not read the full text, so we could not check who paid.
Study · Free full text · about 2 min to read
Free full text on the publisher's site under a CC BY-NC-ND license, as Europe PMC lists it. We could not read the full text. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
An open-label study gave 12 healthy volunteers single doses of two Boswellia serrata forms, in random order. One was a standardized extract, the other its lecithin formulation. Each dose was two 250 mg capsules. Six boswellic acids were measured in blood. KBA did not differ. The other five were higher and were absorbed faster with the lecithin form, by weight and by molar amount. The abstract gives no numbers. Funding: four authors work at Indena; we read only the abstract.
12 healthy men took one dose of boswellia and of dummy capsules; pain-pressure tests differed only at some time points.
Trial · 12 people · Single doses
Prabhavathi et al., Indian Journal of Pharmacology, 2014
Terms and sources
- 12 healthy men
- Aged 18–45, average 36.6. People using painkillers or other medicines that change pain were left out.
- boswellia
- Shallaki, a Boswellia serrata product: two 125 mg capsules once. The report does not name the maker or say whether it is an extract.
- dummy capsules
- Identical placebo capsules, taken 2 weeks before or after boswellia, in random order.
- differed only at some time points
- An analysis across all time points found no difference between products. At 3 hours, pain threshold force rose 9.7% with boswellia and 2.9% with dummy capsules (p = 0.05). Time to pain threshold also rose more with boswellia at 3 hours: 9.7% vs 2.8% (p = 0.04). Pain tolerance rose more with boswellia at 1, 2 and 3 hours (p ≤ 0.01).
- pain-pressure tests
- A device pressed on a finger; no participant reported unwanted events, and blood and urine tests stayed normal.
Study · Free full text · about 15 min to read
Our estimate at about 200 words a minute, from the PMC full text.
Study summary
A trial in Hyderabad, India, gave 12 healthy men aged 18–45 one dose of Shallaki, a Boswellia serrata product. Each took two 125 mg capsules once and identical dummy capsules once, in random order, 2 weeks apart. A device pressing on a finger measured pain threshold and tolerance at 1, 2 and 3 hours. An analysis across all time points found no difference. Single time points differed at some hours. No unwanted events were reported. Funding: the report lists no funding and no conflicts of interest.
Healthy men took a boswellia extract fasting and with a high-fat meal; blood boswellic acids were higher with the meal.
Trial · The abstract does not give the number of participants. · Single doses · funding not stated
Sterk et al., Planta Medica, 2004
Terms and sources
- Healthy men
- The abstract does not give the number of men.
- a boswellia extract
- Three capsules of BSE-018, equal to 786 mg of a dry extract of Boswellia serrata gum resin. Single doses in random order, open label.
- higher with the meal
- Blood levels over time and peak levels of β-boswellic acid, KBA and AKBA were higher with the meal. Two α-boswellic acids were detectable only with the meal. The abstract gives no numbers. The abstract does not say whether the differences were statistically significant.
- funding not stated
- We read only the abstract, which does not say who paid. The authors are at the University of Ulm.
Study · Abstract only · about 2 min to read
Abstract only. Our estimate at about 200 words a minute, from the PubMed abstract.
Study summary
An open study at the University of Ulm gave healthy men single doses of BSE-018. This equals 786 mg of a dry Boswellia serrata gum resin extract. They took it once fasting and once with a high-fat meal, in random order. Blood was sampled for up to 60 hours. Blood levels and peak levels of three boswellic acids were higher with the meal. Two α-boswellic acids were detectable only with the meal. Funding: not stated in the abstract.
Information, not a prescription. Do not start, stop or combine supplements or medicines on your own.